Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors
TAS-115 is a novel MET, VEGFR, FMS and PDGFR inhibitor, developed to improve the continuity of drug administration with a relatively short half-life. We assessed its tolerability, safety, pharmacokinetics, efficacy, and pharmacodynamics in patients with solid tumors. This open-label, dose-escalation...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340670/ https://www.ncbi.nlm.nih.gov/pubmed/31820255 http://dx.doi.org/10.1007/s10637-019-00859-4 |